Skip to content

Infectious Diseases Epidemiology

Our team’s vision is to reduce the burden of infectious diseases in children and their families through comprehensive approaches to understanding the burden of disease, developing and optimising diagnosis and treatment strategies and evaluating and informing current and future prevention programs.

Our group has a particular interest in acute lower respiratory infections, commonly known as chest infections.

These conditions include bronchiolitis and pneumonia and occurs secondary to viral and bacterial infections including viral pathogens respiratory syncytial virus (RSV), influenza, human metapneumovirus and parainfluenza virus and bacterial pathogens including Streptococcus pneumoniae and Bordetella pertussis. Chest infections are a major cause of childhood morbidity with some population subgroups experiencing higher rates of severe disease including Aboriginal and/or Torres Strait Islander children, those with co-morbidities and those from a lower socio-economic background.

The work of the Infectious Disease Epidemiology team centres around three key themes:

  • Burden of Disease – understanding pathogen-specific burden of disease, temporal and seasonal trends in disease and perinatal risk factors to disease in population groups using a range of data sources.
  • Prevention and Policy – evaluating current prevention policy, such as vaccination policy at local and population levels, incorporating assessment of vaccine coverage, cost effectiveness and overall program performance in reducing the incidence of disease. We also use data to advocate for new immunisation programs, including RSV.
  • Diagnosis and Treatment - developing ways to improve surveillance of and the diagnosis and treatment of severe respiratory infections in children through prospective cohort studies, clinical trials and use of administrative health data.

Our team employs an array of methodologies including epidemiological analyses of large-scale population-based linked administrative health data; statistical and mathematical modelling; undertaking prospective cohort studies and clinical trials; and conducting social research.

Team leaders

Professor Hannah Moore
Professor Hannah Moore

OAM BSc (Hons) GradDipClinEpi PhD

Head, Infectious Diseases Research

Professor  Christopher Blyth
Professor Christopher Blyth

MBBS (Hons) DCH FRACP FRCPA PhD

Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases Epidemiology, Wesfarmers Centre of Vaccines and Infectious Diseases, Honorary and NHMRC Emerging Leadership Fellow

Team members (19)

Anita Williams
Anita Williams

MInfecDis MPhil(App Epi)

Research Officer, Infectious Diseases Epidemiology

Belaynew Taye
Belaynew Taye

MD, MPH, PhD

Research Officer, Infectious Disease Epidemiology

Dr Minda Sarna
Dr Minda Sarna

M.App.Epid., PhD

Huong Le
Huong Le

MA (Dev. Econ), MA (App. Stats), PhD (Econ)

Biostatistician & Data Analyst

Liz Wenden
Liz Wenden

MPH PhD

Senior Research Officer

Honorary Team Member

Anastasia Phillips

Anastasia Phillips

Honorary Research Associate

Carolyn Finucane

Carolyn Finucane

Research Nurse

Cathy Pienaar

Cathy Pienaar

Honorary Team Member

Charlie Holland

Charlie Holland

PhD Student

Damien Foo

Damien Foo

Research Officer

Daniel Oakes

Daniel Oakes

PhD Student

Dhruv Shah

Dhruv Shah

Program Manager, Infectious Diseases Epidemiology Team

Fiona Giannini

Fiona Giannini

Mathematical Modeller

Jenna-Lee Rodney

Jenna-Lee Rodney

Aboriginal Project Coordinator

Joanne Harvey

Joanne Harvey

Clinical Trial Coordinator

Leslie-Ann Conway

Leslie-Ann Conway

Honorary Team Member

Mikaela Watson

Mikaela Watson

PhD Candidate

Zoe Clarke

Zoe Clarke

Project Coordinator

Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants

In February 2025, Australia introduced maternal vaccination with bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) in the National Immunization Program for pregnant individuals from 28 weeks' gestation as the primary, year-round strategy to prevent RSV disease in infants 6 months of age or younger.

Infection Triggered Encephalopathies in Australian Children: A National Multicentre Case Series 2013-2024

Infection Triggered Encephalopathy Syndrome (ITES) is a rare but potentially severe complication of infections in children. ITES is a syndrome of acute encephalopathy that occurs in the context of a febrile illness and hypothesised to result from a cytokine mediated infection-triggered cytotoxicity in the central nervous system (CNS) without parenchymal inflammatory cell infiltration. ITES is considered distinct from infectious and immune-mediated encephalitis. We aimed to describe the demographics, associated pathogens, clinical spectrum and outcomes of ITES in Australian children from May 2013 until June 2024.

Mucosal immune cell priming by intranasally delivered Haemophilus haemolyticus is associated with heterologous protection against influenza and nontypeable Haemophilus influenzae

Intranasal vaccines offer a needle-free strategy to enhance immunity to respiratory infections. We investigated the mechanism of action of a novel intranasal vaccine using the human respiratory commensal Haemophilus haemolyticus, previously shown to protect against nontypeable Haemophilus influenzae otitis media and accelerate clearance of influenza A virus.

Using Aboriginal participatory action research within a mixed methods study exploring COVID-19 vaccination uptake in Aboriginal women: a methodological framework for co-design

The COVID-19 pandemic evidenced the critical role of vaccination in reducing the severity of illness and the risk of infection. Despite the policies and efforts of governments to increase vaccination uptake, COVID-19 immunization among Australian Aboriginal pregnant women is lower compared to vaccine uptake of non-Indigenous pregnant women.

Show all
Infectious Diseases Epidemiology

Videos